AJP - GI AJP: Advances in Physiology Education
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Gastrointest Liver Physiol 294: G263-G275, 2008. First published November 8, 2007; doi:10.1152/ajpgi.00267.2007
0193-1857/08 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
294/1/G263    most recent
00267.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, H.
Right arrow Articles by Houghton, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, H.
Right arrow Articles by Houghton, J.

MUCOSAL BIOLOGY

Fas Ag-FasL coupling leads to ERK1/2-mediated proliferation of gastric mucosal cells

Hanchen Li,1,2,* Xun Cai,1,2,* Xueli Fan,1,2 Brian Moquin,1 Calin Stoicov,1 and JeanMarie Houghton1,2

1Department of Medicine, Division of Gastroenterology, and 2Department of Cancer Biology, University of Massachusetts Medical School, Worcester, Massachusetts

Submitted 13 June 2007 ; accepted in final form 2 November 2007

When cells within the gastric mucosa progress from metaplasia to dysplasia to cancer, they acquire a Fas Ag apoptosis-resistant phenotype. It is unusual to completely abolish the pathway, suggesting other forms of Fas Ag signaling may be important or even necessary for gastric cancer to progress. Little is known about alternate signaling of the Fas Ag pathway in gastric mucosal cells. Using a cell culture model of rat gastric mucosal cells, we show that gastric mucosal cells utilize a type II signaling pathway for apoptosis. Under conditions of low receptor stimulation or under conditions where apoptosis is blocked downstream of the death-inducing signal complex, Fas Ag signaling proceeds toward proliferative signaling. Under conditions favoring proliferative signaling, cFLIP is recruited to the Fas-associated death domain-like interleukin-1β-converting enzyme at the death-inducing signal complex and activates ERK1/2. ERK1/2 in turn activates NF-{kappa}B. ERK1/2 stimulates proliferation, whereas NF-{kappa}B activation results in upregulation of the antiapoptotic protein survivin, further promoting proliferation over apoptosis. These results suggest that factors that inhibit apoptosis confer a growth advantage to the cells beyond the survival advantage of avoiding apoptosis and in effect convert the Fas Ag signaling pathway from a tumor suppressor to a tumor promoter.

tumor promoter; cell culture; alternate signaling



Address for reprint requests and other correspondence: J. Houghton, Dept. of Medicine, Univ. of Massachusetts Medical School, LRB 209, 364 Plantation St., Worcester MA 01605 (e-mail: jeanmarie.houghton{at}umassmed.edu)




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
J. C. Symes, M. Kurin, N. E. Fleshner, and J. A. Medin
Fas-mediated killing of primary prostate cancer cells is increased by mitoxantrone and docetaxel
Mol. Cancer Ther., September 1, 2008; 7(9): 3018 - 3028.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2008 by the American Physiological Society.